Maintenance · regain risk

Weight regain risk calculator for after a GLP-1

In trials, people who stopped a GLP-1 regained about 60% of the weight they had lost within a year, levelling off near 75%. Real-world results are often much better: in one 7,938-person cohort, average regain at a year was 0.5% of body weight.

Enter your weights and stop date to see the published average regain curve for your numbers, the real-world range, and the factors that raise or lower your risk. Educational, not a prediction.

By Ian MacCallum, Founder · GLP-Done. Last reviewed . Read our methodology and editorial policy.

An average, not a prediction. The curve is the published average from trials where people stopped with no drug. It does not diagnose or predict your outcome. Regain after a GLP-1 is physiology, not failure, and its degree is reducible.

Leave blank for today.

Example: 210 to 175 lb on semaglutide, stopped 8 weeks ago

Stop13 wk26 wk52 wk78 wkReal-world avgYou are here

Solid line: trial average of 35 lb lost. Dashed: real-world cohort average at 1 year. Shaded: the first 26 weeks, the steepest part of the curve.

After stoppingTrial averageShare of loss
3 months8.6 lb24%
6 months14 lb41%
12 months21 lb60%
Real world, 1 year0.9 lb0.5% of body weight

Where you are

Week 8 of 13

First 90 days, the high-risk window

Hold-the-line weight

179 lb

A check-in trigger, not a target: if your weekly average crosses it, revisit the pillars and talk to your clinician.

Which of these apply to you?

These factors do not change the curve above. Studies link them to less regain but do not give effect sizes precise enough to adjust a projection.

How much weight do people regain after stopping a GLP-1?

StudyWhat happenedTimeframe
Regain trajectory meta-regression (6 trials)Regain followed a curve that levels off near 75% of the weight lost; about 60% had returned by one year, similar across liraglutide, semaglutide and tirzepatideAbout 60 weeks to plateau
STEP 1 extension (semaglutide)People regained about two thirds of the weight they had lost, but stayed about 5.6% below their starting weight1 year after stopping
SURMOUNT-4 (tirzepatide)89.5% of people who stayed on the drug kept at least 80% of their loss, vs 16.6% of those switched to placebo52 weeks
Cleveland Clinic real-world cohort (7,938 people)People with obesity regained an average of 0.5% of body weight; 45% stayed stable or kept losing1 year

Why trials and real life look so different

Trials stop everyone at once and follow them without the drug. In real life, many people restart or switch medications (about 20% restarted and 27% switched in the Cleveland Clinic cohort), had smaller losses to begin with, or stopped for cost rather than by plan. That is why the calculator shows both lines: the trial curve is the clearest picture of the biology, and the real-world line shows that many people do much better.

What raises weight regain risk

FactorEvidenceWhat helps
The first 3 to 6 months offStrong: the curve is steepest hereA plan for the first 90 days
A larger amount lostModerate: regain scales with the size of the lossEarlier, more frequent check-ins
Low protein and muscle lossModerateA protein target
No resistance trainingModerateStrength training
Short or irregular sleepModerateSleep routine
Dropping self-monitoringStrongWeekly weigh-ins
Stopping abruptlyLimited: tapering is barely studiedOrganize a taper with your prescriber

What lowers it

The same habits, in place before appetite returns: protein at most meals (protein targets), lifting 2 to 3 times a week (strength training), 7 to 9 hours of sleep (sleep), small routines that run on autopilot (habit stacking) and a weekly weigh-in (hold the line). The maintenance calorie calculator gives the intake line to watch.

Worked example

Someone went from 210 to 175 lb on semaglutide (35 lb lost) and stopped 8 weeks ago. The trial average projects about 14 lb back by 6 months and about 21 lb by 12 months. The real-world reference is about 1 lb. Their hold-the-line weight is 175 lb plus 2%, about 179 lb: if the weekly average crosses it, that is the cue to revisit the pillars and check in with their clinician.

Your first 26 weeks off the pen

WhenWhat tends to happen
Weeks 1 to 4The drug clears and appetite starts to return (see the clearance timeline)
Weeks 5 to 13The steepest part of the regain curve; routines matter most
Weeks 14 to 26The curve slows; weekly trends tell you whether the plan is working
After 26 weeksRegain tends to level off; keep the check-ins

Read the first 90 days off the pen and why weight comes back after a GLP-1.

FAQ

Questions about this tool

What is the risk of regaining weight after Ozempic or Wegovy?

In the STEP 1 extension, people who stopped semaglutide regained about two thirds of the weight they had lost within a year. Real-world results vary widely, and many people regain much less.

How fast does weight come back after stopping Zepbound or Mounjaro?

Across trials, regain is fastest in the first 3 to 6 months and slows after that. The pooled curve was similar for tirzepatide, semaglutide and liraglutide.

Will I regain all of it?

Not on average. The published curve levels off near 75% of the weight lost, and real-world cohorts often show far less.

What predicts weight regain?

The early months off, a larger loss, low protein and muscle loss, no resistance training, poor sleep, and dropping self-monitoring are all linked to more regain.

Does tapering reduce regain?

The evidence is limited: tapering has barely been studied, though one real-world study saw less regain. Whether and how to taper is your clinician's call.

Does restarting or switching change the picture?

Yes. Many real-world patients restart or switch medications, which is one reason real-world regain looks smaller than in trials. Talk to your clinician about your options.

Is regain my fault?

No. Regain after a GLP-1 is physiology: the drug quiets appetite and that effect fades when it stops. The degree is reducible with habits, but it is not a personal failure.

Does this calculator predict my outcome?

No. It applies a published trial average to your numbers for orientation. Your own trend over the coming weeks is what matters, and your clinician is the right person to interpret it.

Read more

Sources & further reading

Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.

  1. [1]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC
  2. [2]Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionNIH/PMC
  3. [3]Rebound or Retention: A Meta-Analysis of Weight Regain After Discontinuation of GLP-1 Receptor AgonistsNIH/PMC
  4. [4]Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight LossNIH/PMC
  5. [5]Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialNIH/PMC
  6. [6]What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic StudyCleveland Clinic
  7. [7]Impact of Protein Intake During Weight Loss on Preservation of Fat-Free Mass, Resting Energy Expenditure, and Physical FunctionNIH/PMC
  8. [8]Resistance training as a key strategy for high-quality weight loss in men and womenNIH/PMC
  9. [9]Sleep Deprivation: Effects on Weight Loss and Weight Loss MaintenanceNIH/PMC
  10. [10]Characterizing Self-Monitoring Behavior and Its Association With Physical Activity and Weight-Loss MaintenanceNIH/PMC